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 Background: Standard treatment of colorectal cancer includes both cytostatic chemotherapy and targeted therapies. 
Bevacizumab, targeting the VEGF receptor, is one of the primary targeted therapies that achieve better re-
sponse rate and survival rate as compared to combination chemotherapy. To the best of our knowledge, there 
is no established single marker that can be used as a predictive marker in bevacizumab therapy.
 Material/Methods: We enrolled 24 patients with the diagnosis of metastatic colorectal cancer in our study. During the study, 2 
blood samples were drawn from patients before the first cycle and after the sixth cycle of bevacizumab ther-
apy. Serum levels of VEGF, ANG II, and NO were recorded.
 Results: While the change across VEGF levels was found to be a statistically significant decreasing trend (p=0.009), this 
decrease was not found to be correlated with treatment response and hypertension development. Additionally, 
no statistically significant difference was found in terms of NO and ANG II levels.
 Conclusions: This study showed a significant decrease in serum VEGF, but failed to show a significant change in NO and 
ANG II levels during bevacizumab treatment. Although no significant correlation was found between the pres-
ence of hypertension and markers, most patients (83%) had an increase in their blood pressure. Our results 
suggest that dynamic monitoring of NO and ANG II, along with VEGF, may not be useful as predictive markers 
for bevacizumab treatment in colorectal cancer.
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Background
Colorectal cancer is the one of the most lethal cancers. On 
the other hand, significant improvement in survival has been 
achieved as a result of the introduction of cancer screening pro-
grams, the advancements in diagnostic methods in molecular 
oncology, and the implementation of more efficient cytostatic 
chemotherapies and targeted therapies in the past 2 decades.
Bevacizumab is a recombinant humanized monoclonal antibody 
with high binding specificity for vascular endothelial growth 
factor (VEGF). Bevacizumab recognizes and inhibits all of the 
important isoforms of VEGF. VEGF inhibition affects endotheli-
al cells and tumor vascularization in several ways. Endothelial 
cells cannot mature in the absence of VEGF, thus the forma-
tion of new vessels is inhibited and existing vessels regress 
[1,2]. However, inhibition of VEGF could lead to severe hyper-
tension (HT), which carries high risk of mortality, particularly 
if necessary precautions are not taken.
Although hypertension and cancer are 2 independent diseas-
es, angiogenesis plays a significant role in the development 
of both diseases. When the balance between proangiogenic 
and anti-angiogenic factors shifts toward angiogenic factors, 
angiogenesis cannot be controlled [1,2] and excessive produc-
tion of VEGF, nitric oxide (NO), and angiotensin II (Ang II) is ob-
served. Inhibition of these pathways in clinical trials can im-
prove survival. However, inhibition of angiogenesis can cause 
serious effects on microvascular structure and leads to spe-
cific side effects, known as ‘class side effects’, consisting pri-
marily of bleeding and hypertension [3]. Many studies have 
shown that hypertension can depend on the dose and dura-
tion of treatment; it is observed in about 30% of the cases and 
the incidence of grade 3 and higher HT is about 8–10% [4–6].
In this study, we tried to evaluate the effect of VEGF inhibition 
on blood pressure and serum levels of VEGF, nitric oxide and 
angiotensin II to determine whether these biochemical markers 
can be used to predict long-term efficacy and toxicity of these 
specific treatments in advanced colorectal cancer patients.
Material and Methods
We enrolled 24 patients with metastatic colorectal cancer who 
were followed up between April 2010 and May 2011 at the 
outpatient clinic of the Division of Medical Oncology, Adana 
Practice and Research Center, Başkent University, Adana, Turkey. 
The main inclusion criteria were aged over 18 years, diagno-
sis with metastatic colorectal disease, ECOG PS under stage 3, 
no known renal disease, and any contraindication for bevaci-
zumab combination chemotherapy. All patients gave written 
informed consent. The patients rested in sitting position for 
5 minutes, then their basal blood pressure was measured us-
ing an appropriate size of cuff. The patients were taught how 
to measure and record their blood pressure at home 2 times 
per day and they were asked to record these measurements 
on a blood pressure evaluation form. Six cycles of combina-
tion chemotherapy consisting of 5 fluorouracil + leucovorin 
+ irinotecan and bevacizumab were given to all patients ev-
ery 14 days. In all patients, 2 blood samples of 2 cc were ob-
tained, 1 before the treatment and the other during the 3rd 
month of therapy (after 6 cycles), and these samples were used 
to investigate the serum levels of VEGF, NO, and Ang II. For 
the quantitative measurement of the VEGF levels, ELISA was 
used (Human VEGF ELISA Kit, RayBiotech, Inc., Norcross, GA). 
Serum levels of NO were determined using colorimetric meth-
od (Roche Diagnostics GmbH, Mannheim, Germany). Ang II lev-
els were determined using an ELISA kit (Human Angiotensin II 
ELISA kit, Cusabio Biotech, Wuhan, China).
Statistical methods
Statistical analysis of the data was performed using SPSS 17.0 
software. Categorical measurements are expressed as number 
and percentage and continuous measurements are expressed 
as median and minimum-maximum. Intergroup comparison of 
the categorical measurements was done using the chi-square 
test. For the general intergroup comparison of continuous 
measurements, one-way analysis of variance was used if the 
hypotheses could be met and Kruskal-Wallis test was used if 
the hypotheses could not be met. Paired comparisons of the 
groups were done using Bonferroni or Scheffe tests. Because 
some continuous measurements did not meet the hypothesis 
of normal distribution, the correlation across these continu-
ous measurements was examined using the Spearman coef-
ficient of correlation. All tests were performed at 95% confi-
dence level and with a=0.05 error value.
Results
Of 24 patients, 15 (62.5%) were male and mean age was 61 
years (range: 37–75) years. The patients had diagnosed as co-
lon and rectum cancer in 19 (79.2%) and 5 (20.8%), respec-
tively. Initial presentation with metastatic disease was detect-
ed in 20 (83.3%) patients. During the initial evaluation, 19 of 
the patients (79.2%) were found normotensive. Demographic 
and clinicopathologic characteristics of the study patients are 
summarized in Table 1.
Biochemical results obtained from the serum samples of 
the patients
Blood samples were drawn at baseline and at the end of 6 cy-
cles for the investigation of serum levels of VEGF, NO, and ANGII. 
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According to the result of the blood sample analysis, median 
levels of VEGF, NO, and ANGII were 197.7 pg/mL, 6.32 pg/mL, 
and 4.51 pg/mL at baseline and 87.5 pg/mL, 6.71 pg/mL, and 
3.55 pg/mL at the end of 6 cycles, respectively. The change 
across VEGF levels was found to be a statistically significant 
decreasing trend (p=0.009). The results are given in Table 2.
Number (n) Percentage (%)
Number of patients 24 100
Age
 Mean 61 (range 37–75) –
Gender 
 Female 9 37.5
 Male 15 62.5
Tumor localization
 Colon 19 79.2
 Rectum 5 20.8
Histologic grade
 Grade 2 9 37.5
 Grade 3 15 62.5
History of hypertension at the time of admission
 Yes 5 20.8
 No 19 79.2
Presence of uncontrolled hypertension 0 0
Presence of diabetes at the time of admission
 Yes 3 12.5
 No 21 87.5
Presence of uncontrolled diabetes 0 0
Smoking 
 Yes 13 54.2
 No 11 45.8
History of adjuvant chemotherapy 
 Yes 4 16.7
 No 20 83.3
Table 1. Demographical and clinicopathological characteristics of the study patients.
Baseline
(median, min–max)
At the end of 6th cycle
(median, min–max)
VEGF  197.7 (8.2–681.6)  87.1 (12.4–141.2) P=0.009
NO  6.32 (2.5–21.5)  6.7 (2.9–28.9)
ANG II  4.51 (1.2–10.8)  3.55 (1.58–8.9)
Table 2. Serum tumor marker, VEGF, NO and ANG II levels of the patients at baseline and at the end of 6th cycle of therapy.
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The patients were asked to measure and record their blood 
pressure 2 times per day using a digital blood pressure mea-
surement device during their examination in the outpatient 
clinic and at home during the time interval between 2 chemo-
therapy courses. In addition, blood pressure of the patients 
was measured during the control visit. Accordingly, all measure-
ments of the patients were recorded in the statistical software 
and analyzed for development of hypertension during their 
follow-up. One patient (4.2%) did not develop hypertension, 
5 patients (20.8%) had prehypertension, 15 patients (62.5%) 
had Stage 1 hypertension, and 3 patients (12.5%) had Stage 
2 hypertension. None of the 5 patients who had hypertension 
at baseline showed an imbalanced change in blood pressure 
levels. Three (12.5%) of the patients had no hypertension at 
baseline, which was needed for the initiation of antihyperten-
sive drug treatment. In several cycles due to the development 
of Stage 2 hypertension and thereafter, the blood pressure of 
these patients were also controlled. Figure 1 shows the per-
centage of patients that developed hypertension after beva-
cizumab treatment.
Statistical analysis failed to show a significant correlation be-
tween the development of hypertension and serum levels of 
VEGF, NO, and ANGII obtained at baseline at the end of the 
6th cycle of the therapy. The levels of ANG II were found to be 
higher, although not significantly so, in the patients who de-
veloped hypertension when compared with patients who were 
normotensive at the end of the 6th cycle (p=0.09). However, 
the degree of decrease was not found to be correlated with 
response to the chemotherapy and hypertension development 
(r>0.1). Figure 2 shows the correlation between serum ANG II 
levels and presence of hypertension.
Discussion
The rationale of anti-angiogenic treatment is based on the 
hypothesis by Dr. Judah Folkman, which was published in an 
article titled ‘Tumor growth and metastasis is an angiogene-
sis-dependent process’ [7]. This hypothesis was validated in 
many clinical and experimental studies [8–10]. Bevacizumab, an 
IgG1-like monoclonal antibody developed against VEGF, is the 
most commonly used anti-angiogenic molecule and has been 
shown to have a statistically significant increase in response 
and survival rate in a wide range of tumors. Bevacizumab 
was approved for treatment of colon, breast, lung, and ovari-
an cancer, and also treatment of glioblastoma multiforme [11].
In our study, in 24 patients with complete follow-up, the levels 
of VEGF, NO, and ANG II and blood pressure were measured at 
baseline and at the end of 6 therapeutic cycles. Although, when 
changes in the level of VEGF, NO, and ANG II from baseline to 
the end of 6 cycles were examined, only VEGF levels showed 
a statistically significant decrease (p=0.009). Additionally, we 
found that all patients except 1 showed some degree of in-
creased blood pressure.
The correlation between the use of VEGF inhibitors and serum 
levels of VEGF has been examined in many studies, some of 
which investigated the correlation between pre-treatment se-
rum VEGF levels and response, whereas others examined the 
correlation between drug-dependent increase and decrease 
of serum VEGF levels. Clinical studies showed that VEGF lev-
els increased with treatment using oral tyrosine kinase inhib-
itors with intrinsic anti-VEGF properties, whereas VEGF levels 
decreased with the treatment of bevacizumab [12–16]. Some 
studies have suggested that the effect of bevacizumab on VEGF 
Figure 1.  Hypertension development percentage after 6th cycles 
of bevacizumab treatment.
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Figure 2.  Correlation between serum levels of ANG II and 
hypertension in the patients at the of 6th cycle of the 
therapy.
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levels can be affected by concomitant chemotherapeutics. Only 
1 clinical study in which bevacizumab was initiated as a single 
agent or in combination with chemotherapy showed increased 
VEGF levels in the single-agent arm and decrease of VEGF lev-
els in the combination arm [17]. Unfortunately, the only stud-
ies that showed the change of only VEGF levels with anti-an-
giogenic treatment had neither prognostic nor predictive value 
[18–21]. In our study, there was a statistically significant de-
crease in VEGF levels with bevacizumab therapy, but we did 
not find any correlation between degree of decrease and inci-
dence of hypertension. We suggest that this result can be ex-
plained by the small number of patients in our study group.
Experimental studies in mice demonstrated that intravenous 
and infusional VEGF led to vasodilatation and lowered blood 
pressure by increasing endothelial and renal levels of NO and 
prostacyclines [22,23]. The authors in these studies hypothe-
sized that VEGF inhibition may cause a decrease in NO levels 
and this decrease shows an inverse correlation with hyper-
tension [24]. Bevacizumab was shown to be associated with 
decreased NO levels in 1 in vitro experimental study [25]. In 
the literature, there are a limited number of clinical studies 
that investigated the possible interplay between bevacizum-
ab therapy and serum levels of NO and ANG II; they failed to 
show a significant decrease in these biochemical markers with 
Anti-VEGF therapy [26]. An experimental study performed by 
Facemire et al. reported a significant decrease in urinary ex-
cretion of renin mRNA and aldosterone levels with VEGF inhi-
bition when compared with the control group [27]. A clinical 
study by Veronese et al. reported unchanged serum creatinine, 
aldosterone, and renin concentrations with sorafenib treatment 
[28]. Results of our study also failed to show a significant ef-
fect of bevacizumab on NO and ANG II levels.
In the literature, incidence of hypertension after initiation of 
bevacizumab was observed in studies at a rate of 30–80% for 
all stages and 10–15% for CTC Stage 3 or JNC 7 Stage 2 HT 
[29,30]. In our study, all patients except 1 developed hyper-
tension. This high incidence rate of hypertension may be ex-
plained by the more frequent measurement of blood pressure 
due to study protocol.
In the present study, we aimed to evaluate alteration and in-
terplay between serum levels of VEGF, NO, and ANG II during 
anti-angiogenic treatment and to use these biochemical mark-
ers to predict long-term efficacy and toxicity of this targeted 
therapy. We found a significant decrease in serum VEGF lev-
els but failed to show a significant change in NO and ANG II. 
Also, our study failed to show interplay between VEGF, NO, 
and ANGII levels.
Conclusions
We suggest that more intensive follow-up of blood pressure dur-
ing bevacizumab treatment may be needed. Dynamic measure-
ment of NO and ANG II along with VEGF serum levels may not 
be used as predictive marker during bevacizumab treatment.
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